Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of
camrelizumab combined famitinib in subjects with selected advanced solid tumor.